Publications by authors named "Maria Fernanda Zavala-Miranda"
Article Synopsis
- The study investigates the use of urine epidermal growth factor (EGF) as a biomarker to predict recovery in patients with severe kidney impairment due to glomerulonephritis.
- It involved 82 subjects, primarily with lupus nephritis and ANCA-associated vasculitis, measuring the EGF levels in their urine to determine their chances of regaining kidney function.
- Results showed that higher levels of urine EGF correlated with better recovery rates, suggesting EGF is a reliable indicator for assessing the potential for kidney function recovery in these patients.
Introduction/objectives: The heterodimer exostosin-1/exostosin-2 (EXO-1/2) is a novel antigen observed in membranous nephropathy associated with systemic lupus erythematosus. This study aimed to evaluate the association between EXO-1/2 positivity in kidney biopsy and kidney outcomes.
Methods: The kidney biopsy tissue from 50 class 5 lupus nephritis (LN) and 55 mixed class 3/4 + 5 LN patients was stained for EXO-1/2.
Objectives: To evaluate the effect of antimalarial drugs in response to therapy, incidence of LN flares, and progression of kidney disease in a large LN cohort.
Methods: We retrospectively studied 424 biopsy-proven LN patients followed for >3 years. We obtained demographic, clinical, laboratory, histopathological and treatment variables.
Introduction/objectives: Acute kidney injury (AKI) with the requirement of kidney replacement therapy (KRT) portends a poor prognosis for kidney function in lupus nephritis (LN). This study evaluated the kidney function recovery rates, the rates of reinitiation of KRT, and factors associated with these outcomes in LN.
Method: All consecutive patients hospitalized for LN with KRT requirement between 2000 and 2020 were included.
Background: Repeated renal flares in lupus nephritis (LN) have been associated with worse long-term kidney function. This study aimed to assess the impact of repeated LN flares in response to therapy, kidney and patient prognosis.
Methods: All patients from a biopsy-proven LN cohort between 2008 and 2018 were segregated into three groups according to the number of LN flares when they entered our cohort: first LN flare, second LN flare or third LN flare.
Objectives: The present study aims to assess the course of uMCP-1 and its association with response to therapy and long-term kidney function in a prospective cohort of adults who received a kidney biopsy for suspicion of active lupus nephritis (LN).
Methods: Subjects were segregated into a histologically active LN group and a histologically chronic LN group. Both groups were followed for > = 36 months and urine were collected at flare, 3, 6, and 12 months of follow-up.
Objectives: To characterize the clinical presentation and outcomes of LN in a Hispanic cohort from Mexico.
Methods: We studied 440 subjects with systemic lupus erythematosus and biopsy-proven LN followed for >36 months. We obtained demographic, clinical, laboratory, histopathological and treatment variables.